Group of Hong LIANG
Supervisors
Prof. Dr. Hong Liang

Prof. Dr. Hong Liang


Tel: + 86- (0)773- 2565678/+ 86- (0)773- 3560088

E-mail: hliang@mailbox.gxnu.edu.cn

 

Prof. Dr. Hong Liang is currently the vice chairman of GuangxiAssociation for Science and Technology, director of the State Key Laboratoryfor Chemistry and Molecular Engineering of Medicinal Resources, Ministry ofEducation, and a supervisor for Ph. D program in Guangxi NormalUniversity, Ph.D programs of Inorganic Chemistry in Nankai University andNanjing University, and Ph.D program of Applied Chemistry in Central SouthUniversity. He served as the president of Guangxi Normal University from Jan.2002 to July 2017.

  

IIn scientific research, he has so far led more than 30 projectsand programs, including one Key National Natural Science Fund Project, three 973 pre-special programs, and seven National Natural Science Fund Projects.Among about 500 papers he published in the SCI key journals like Nat. Commun., JACS, Angew. Chem.. Int. Ed., Coord. Chem. Rev., J. Med. Chem., Small, Chem.Comm., Eur. Chem. J., Eur. J. Med. Chem., Inorg. Chem., Anal. Chem., J. Inorg. Biochem., Mol. Pharm., and his papers have been cited for over 11800 times in SCI journals, and H-index is 56. Furthermore, he has possessed more than 60 authorized invention patents in China. For his outstanding academicachievements, he was awarded quite a few prizes and honorary titles, such as,Fellow of Royal Society of Chemistry(FRSC), Editorial Board Member for Journalof Inorganic Biochemistry(JIB) , Journal of Natural Medicines Research(JNMR), and so on.

 

Research Interests

1. Pharmacological effects of active components of traditional chinese medicine in metal-based anti-tumor drugs

2. Novel metal-based anti-tumor drugs and drug delivery system of protein

1Mechanism of cell migration

2DNA and Protein based design of novel metal-based anti-tumor drugs

3Protein nanoparticle drug delivery system

3. Integration of diagnosis and treatment of nanoparticle materials

4. New method of real-time in-situ monitoring of life process

 

Social service

1. Fellow of Royal Society of Chemistry, UK

2. Director of Chinese chemistry Association

3. Member of Inorganic Chemistry Committee of Chinese chemistry Association

4. Member of Applied Chemistry Committee of Chinese Chemistry Association

5. Honorary director of Chemistry and Chemical Industry Society of Guangxi

6. Guest editor for Current Pharmaceutical Design

7. Member of editorial board for Journal of Inorganic Biochemistry, Chinese Journal of Inorganic Chemistry, Journal of Chemistry Education

 

Course

Bioinorganic Chemistry

 

Recent Publications

Articles

1.  Ke-BinHuang, Feng-Yang Wang, Yuan Lu, Liang-Mei Yang, Nian Long, Shan-Shan Wang,Zhiying Xie, Matthew Levinec, Taotao Zou*, Jonathan L. Sessler*, Hong Liang*. Cu(II) complex thatsynergisticallypotentiates cytotoxicity and an antitumor immune response bytargeting cellularredox homeostasis. PNAS, 2024, 121(24), e2404668121.

2.  XueyuMan , Wenjuan Li , Minghui Zhu , Shanhe Li , Gang Xu , Zhenlei Zhang , HongLiang*, Feng Yang*. Anticancer Tetranuclear Cu(I) Complex Catalyzes a ClickReaction to Synthesize a Chemotherapeutic Agent in situ to Achieve TargetedDual-Agent Combination Therapy for Cancer. Angew. Chem. Int. Ed., 2024 DOI: 10.1002/anie.202411846.

3.  PeijingXu, Changchun Wen, Cunji Gao*, Huihui Liu, Yingshu Li, Xiaolu Guo, Xing-CanShen*, Hong Liang*. Near-Infrared-II-ActivatableSelf-Assembled ManganesePorphyrin-Gold Heterostructures for PhotoacousticImaging-GuidedSonodynamic-Augmented Photothermal/Photodynamic Therapy. ACS Nano, 2024, 18,713−727.

4.  YuanLu, Shan-Shan Wang, Meng-Ya Li, Rong Liu, Meng-Fan Zhu, Liang-Mei Yang,Feng-Yang Wang, Ke-Bin Huang*, Hong Liang*. Cyclometalated iridium(III) complexbased on isoquinoline alkaloid synergistically elicits the ICD response and IDOinhibition via autophagy-dependent ferroptosis. Acta Pharm. Sin. B, 2024, DOI: 10.1016/j.apsb.2024.06.017.

5.  YulongBai, Jing Hua, Jingjin Zhao*, Shulong Wang, Mengjiao Huang, Yang Wang, YanniLuo, Shulin Zhao*, Hong Liang*. A Silver-Induced Absorption Red-ShiftedDual-Targeted Nanodiagnosis-Treatment Agent for NIR-II PhotoacousticImaging-Guided Photothermal and ROS Simultaneously Enhanced Immune Checkpoint Blockade Antitumor Therapy. Adv. Sci., 2023, 2306375.

6.  Qi-Yuan Yang+, Rui Ma+,Yun-Qiong Gu+, Xiao-Fang Xu, Zhen-Feng Chen*, Hong Liang*. Arene-Ruthenium(II)/Osmium(II) Complexes Potentiate the Anticancer Efficacy of Metformin via GlucoseMetabolism Reprogramming. Angew. Chem. Int. Ed., 2022, e202208570.

7.  Xiaolin XiongⅡ, Ke-Bin HuangⅡ, Yuan WangⅡ, Bei Cao, Yunli Luo, Huowen Chen, Yan Yang, Yan Long, MoyiLiu, Albert S. C. Chan, Hong Liang*, Taotao Zou*. Target Profiling of anIridium(III)-Based Immunogenic Cell Death Inducer Unveils the Engagement of Unfolded Protein Response Regulator BiP. J. Am. Chem. Soc., 2022,144, 23, 10407–10416.

8.  Yan-Lei Ma*, Ji-Ping Yue*, Yao Zhang*, Chen-Zhang Shi*,Matt Odenwald, Wenguang G. Liang, Qing Wei, Ajay Goel, Xue-Wen Gou, JamieZhang, Shao-Yu Chen, Wei-Jen Tang, Jerrold R. Turner, Feng Yang, Hong Liang*, Huan-Long Qin, Xiao-YangWu. ACF7 regulates inflammatory colitis and intestinal wound response byorchestrating tight junction dynamics. Nat. Commun. 2017,8, 15375.

9.  Ji-Ping Yue, Yao Zhang, Wen-Guang G. Liang, Xue-Wen Gou,Philbert Lee, Han Liu, Wan-Qing Lyu, Wei-Jen Tang, Shao-Yu Chen, Feng Yang*, Hong Liang*, Xiao-Yang Wu*. InVivo Epidermal Migration Requires Focal Adhesion Targeting of ACF7. Nat.Commun. 2016, 7, 11692.

10.  Yi Gou, GuoJin Huang , Jinlong Li, Feng Yang*, Hong Liang*. Versatile delivery systemsfor non-platinum metal-based anticancer therapeutic agents, Coordin.Chem. Rev., 2021, 441, 213975.

11.  Wenjuan Li, Shanhe Li, Zhenlei Zhang, GangXu, Xueyu Man, Feng Yang*, Hong Liang*. Developing a Multitargeted AnticancerPalladium(II) Agent Based on the His-242 Residue in the IIA Subdomain of HumanSerum Albumin. J. Med. Chem., 2023, 66, 8564–8579.

12.  XingLu, Mei-Feng Wu, Jiang-Lun Wu, Hai-Qun Zhang, HongLiang*, Zhen-Feng Chen*. Platinum-Based Mcl‑1 Inhibitor Targeting Mitochondria Achieves Enhanced Antitumor Activity asa Single Agent or in Combination  withABT-199.J. Med. Chem., 2023, 66, 8705−8716.

13.  ZhenleiZhang†, Juzheng Zhang†, Tongfu Yang†, Shanhe Li, Gang Xu, Hong Liang*,Feng Yang*. Developing an Anticancer Platinum(II) Compound Based on theUniqueness of Human Serum Albumin. J. Med. Chem., 2023,66,5669−5684.

14.  XueyuMan§, Tongfu Yang§, Wenjuan Li, Shanhe Li, Gang Xu, Zhenlei Zhang, Hong Liang*,Feng Yang*. Developing a Gadolinium(III) Compound Based on Apoferritin forTargeted Magnetic Resonance Imaging and Dual-Modal Therapy of Cancer. J. Med. Chem., 2023,66, 7268−7279.

15.  TongfuYang, Zhenlei Zhang, Juzheng Zhang, Yanping Li, Wenjuan Li, Hong Liang*,Feng Yang*. Developing a Gallium(III) Agent Based on the Properties of theTumor Microenvironment and Lactoferrin: Achieving Two-Agent Co-delivery andMulti-targeted Combination Therapy of Cancer. J. Med. Chem., 2023,66,793−803.

16.  Shuang Kan, Rong Li, Yanhui Tan, Fang Yang, Shaohua Xu, Lingzhu Wang, Lijun Zhang, Xuchen Sun, Xuanming Chen, Yuting Yang, Wei Shu, Huaibin Wan, Zheng-Feng Chen, Hong Liang*, Ming Chen*. Latexin deficiency attenuates adipocyte differentiation and protects miceagainst obesity and metabolic disorders induced by high-fat diet. Cell Death & Disease,2022,13(2):175 .

17.  Wen-Ying Shen, Chun-Peng Jia, Li-YiLiao,Liu-Lin Chen, Cheng Hou, Yang-Han Liu, Hong Liang*, Zhen-Feng Chen*. Copper(II) Complexes ofHalogenated Quinoline Schiff Base Derivatives Enabled Cancer Therapy throughGlutathione-Assisted Chemodynamic Therapy and Inhibition of Autophagy Flux.  J. Med. Chem., 2022, 65,5134-5148.

18.  Ming Jiang, Yong Chu, Tongfu Yang, WenjuanLi, Zhenlei Zhang, Hongbin Sun, HongLiang*, Feng Yang*. Developing a Novel Indium(III) AgentBased on Liposomes to Overcome Cisplatin-Induced Resistance in Breast Cancer byMultitargeting the Tumor Microenvironment Components. J. Med. Chem.,2021,64, 14587–14602.

19.  ShulongWang, Jingjin Zhao, Liangliang Zhang*, Chaobang Zhang, Zhidong Qiu, Shulin Zhao*. Yong Huang, Hong Liang*. A Unique MultifunctionalNanoenzyme Tailored for Triggering Tumor Microenvironment Activated NIR-IIPhotoacoustic Imaging and Chemodynamic/Photothermal Combined Therapy. Adv. Healthcare Mater.,2021,2102073.

20.  Juzheng Zhang, Ming Jiang, Shanhe Li, ZhenleiZhang, Hongbin Sun, Feng Yang*, Hong Liang*. Developing a NovelAnticancer Gold(III) Agent to Integrate Chemotherapy and Immunotherapy. J. Med. Chem., 2021, 64, 6777–6791.

21.  Ju-Zheng Zhang, Zhen-Lei Zhang, MingJiang, Shan-He Li, Hao-Liang Yuan, Hong-Bin Sun, Feng Yang*, Hong Liang*. Developing a novelgold(III) agent to treat glioma based on the unique properties of apoferritinnanoparticles: inducing lethal autophagy and apoptosis,J. Med. Chem., 2020, 63, 13695–13708.

22.  Noor Shad Gul†, Taj-MalookKhan1†, Yan-Cheng Liu, Muhammad Iqbal Choudhary, Zhen-Feng Chen*, HongLiang*. Pd(II) and Rh(III) Complexes with Isoquinoline DerivativesInduced Mitochondria-Mediated Apoptotic and Autophagic Cell Death in HepG2Cells, CCS Chem., 2020, 2, 1626–1641.

23.  Xing Lu, Yan-Cheng Liu, Chris Orvig, HongLiang*, Zhen-Feng Chen*. Discovery of aCopper-Based Mcl‑1 Inhibitor as an Effffective Antitumor Agent, J. Med.Chem., 2020, 63, 9154–9167.

24.  Zhen-Lei Zhang, Ping Yu, Yi Gou,Ju-Zheng Zhang, Shan-He Li, Mei-Ling Cai, Hong-Bin Sun, Feng Yang*, HongLiang*. A novel brain-tumor-inhibitingcopper(II) compound based on HSA–cell penetrating peptide conjugate. J. Med. Chem., 2019, 62, 10630–13069.

25.  Ke-Bin Huang, Feng-Yang Wang, Xiao-Ming Tang, Hai-WenFeng, Zhen-Feng Chen*, Yan-Cheng Liu, You-Nian Liu, Hong Liang*. Organometallic Gold(III) Complexes Similar to TetrahydroisoquinolineInduce ER-Stress-Mediated Apoptosis and Pro-Death Autophagy in A549 CancerCells.J. Med. Chem.,2018,61, 3478-3490.

26.  Bang-Ping Jiang, Li Zhang, Xiao-Lu Guo,Xing-Can Shen*, Yan Wang, Yang Zhu,HongLiang*. Poly(N-phenylglycine)-Based Nanoparticles as HighlyEffective and Targeted Near-Infrared Photothermal Therapy/PhotodynamicTherapeutic Agents for Malignant Melanoma. Small,2017, 13, 1602496.

27.  Zhen-FengChen*, Qi-Pin Qin, Jiao-Lan Qin, Jie Zhou, Yu-Lan Li, Nan Li, Yan-Cheng Liu, Hong Liang*.Water-soluble ruthenium(II) complexes with chiral4-(2,3-Dihydroxypropyl)-formamide oxoaporphine (FOA): in vitro and in vivoanticancer activity by stabilization of G-Quadruplex DNA, inhibition oftelomerase activity, and induction of tumor cell apoptosis. J. Med. Chem. 2015, 58, 4771–4789.

28.  Zhen-FengChen*, Qi-Pin Qin, Jiao-Lan Qin, Yan-Cheng Liu, Ke-Bin Huang, Yu-Lan Li, TingMeng, Guo-Hai Zhang, Yan Peng, Xu-Jian Luo, Hong Liang*.  Stabilization of G-quadruplex DNA, inhibition oftelomerase activity, and tumor cell apoptosis by organoplatinum(II) complexeswith oxoisoaporphine. J. Med. Chem.,2015, 58, 2159–2179.

29.  Ming-Hua Zeng*, Min-XiaYao, Hong Liang*, Wei-XiongZhang, Xiao-MingChen. A Single-Molecule-Magnetic, Cubane-Based, Triangular Co12Supercluster. Angew. Chem. Int. Ed., 2007, 46, 1832–1835.

30.  Yi Gou*, Li Liu, Hong Liang*. Editorial on the Research Topic: The Developments of Metal-Based Agents Against Lung Cancer. Front Pharmacol., 2022,13, https://doi.org/10.3389/fphar.2022.1101890.


Editorial Articles

1. Editorial: Thedevelopments of metal-based agents against lung cancer, Frontiers in Pharmacology. Front. Pharmacol., 08 December 2022

2. HSA IIA subdomain-baseddeveloping anticancer metal pro-drug: a new and improved approach. FutureMed Chem., 2016, 8: 89-91.

3. HSA-based drugdevelopment and drug delivery systems. Curr Pharm Design.,2016, 21: 1784. (Medical Science SCI Division 2)  

4. HSA-basedanti-inflammatory therapy: a new and improved approach. Future MedChem., 2014, 6: 119-21. (Medical Science SCI Division 2)


  

Research Projects

1. Training Projectfor Candidates for the Academician of the Chinese Academy of Engineering (2017.1-2021.12,¥ 15,000,000)

2. National NaturalScience Foundation of China (Major Program): Developing Metal-based Anti-tumorComplexes from Active Components of Traditional Chinese Medicine (2015.1-2019.12,¥ 3,600,000)

3. Project of Plan973: A Research on Developing Metal-based Anti-tumor Complexesfrom Active Components of Traditional Chinese Medicine and Chemical Assembly and ActivityEvaluation on Natural Cyclic Peptide Potential Drugs (2012-2015, ¥2,550,000)

4. Innovative Teams Project of Ministry ofEducation of China (Academic Leader, rank No.2) : (2013-2016, ¥ 4,500,000; 2017-2019, ¥ 3,000,000)

5. NationalNatural Science Foundation of China No. 21171043: A Research on theInteraction Among Anti-tumor Phytomedicines,Metal-based Drugs and Human Serum Albumin(2012.1-2015.12, ¥ 800,000)


Titles

1. Leading Talent of National “Ten-thousand Talents Program” 2016

2. Firstly Selected Candidates from Guangxi for the Academician of the Chinese Academy of Engineering 2016

3. Award for Special Contribution in Development of the West Regions in China 2008 (China Association for Science and Technology)

4. National Excellent Worker Advanced in Science and Technology 2005

5. 3rd Youth Teacher of Higher Education Award Winner 2002 (China’s Ministry of Education)

6. China Youth Science and Technology Award Winner 2001

7. China’s National Youth Scholar of Outstanding Contribution 1999

8. Guangxi Excellent Professional Technician 1999

9. First Level Candidates for Guangxi “Ten, Hundred, Thousand Talents Project” 1998

10. Firstly Selected Candidates for National Hundred-Thousand-Ten Thousand Talents Project 1996

11. Special government allowances of the State Council 1996

12. Guangxi Excellent Expert 1996


Clicks: 79 Update Time: 2022-12-22